The SMRwt peptide reduces the expression of Mortalin, which could play a role in breast cancer cell invasion and metastasis, thus suggesting potential peptide applications in early-stage breast cancer chemotherapy. This evidence concerns the gene HSPA9 and breast carcinoma.